Tag Archives: atrial fibrillation risk

The relationship between GLP-1 therapies and atrial fibrillation is an emerging topic in diabetes care, raising an important question: could medications designed to protect the heart also influence its rhythm? Patients with diabetes already face a higher risk of atrial fibrillation, so understanding how these GLP-1 receptor agonists affect cardiac …

The potential link between GLP-1 therapies and atrial fibrillation is drawing increasing clinical interest as cardiometabolic care continues to evolve. Patients with type 2 diabetes face a significantly higher risk of atrial fibrillation, yet GLP-1 receptor agonists are rarely discussed in rhythm management conversations. Could medications such as semaglutide (Ozempic), …